
Apollo Hospitals Enterprise Gears Up for Q3 Reveal on 10th February; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 9 Feb 2026 • 11:57 am
Posted by:

Apollo Hospitals Enterprise's Q3 results FY26 are scheduled to be announced on 10th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Apollo Hospitals Enterprise Q3 Results 2026 Preview
- Apollo Hospitals Enterprise's revenue is expected to be in the range of ₹5,526.90 crore, a 1.12% YoY increase.
- Profit After Tax, or PAT, is projected to fall 1.72% YoY.
- Net profit is ₹372.30 crore, down 1.72% YoY
- EBITDA to fall 8.57%
Apollo Hospitals Enterprise Share Performance
- Over the past six months, Apollo Hospitals Enterprise's share price has fallen by 1.13% to ₹7,177.00.
- Moreover, over the past year, the stock has increased by 6.15%.
- Despite this weak short-term performance, Apollo Hospitals Enterprise's stock has delivered a financially sound 161.09% return over the past 5 years.
- As of 9th February 2026, the stock traded at ₹9.00 per share.
About
Apollo Hospitals Enterprise Limited is an Indian multinational healthcare company based in Chennai. It is the country’s largest private, for-profit hospital network, operating 71 owned and managed hospitals. In addition to its flagship hospital chain, the group runs pharmacies, primary care and diagnostic centres, telehealth clinics, and digital healthcare services through its subsidiaries. Apollo Hospitals recorded an increase in revenue of ₹21,794 crore, operating income rose by ₹3,022 crore, and net income grew by ₹1,446 crore. During the same period, total assets increased by ₹20,657 crore
Key Factors to Watch for Apollo Hospitals Enterprise Q3 Results FY26
- Revenue Growth: Performance of hospital, pharmacy, and digital health segments, and their contribution to overall topline growth.
- Occupancy Rates & ARPOB: Trends in bed occupancy and Average Revenue Per Occupied Bed, reflecting demand and pricing power.
- Margin Performance: EBITDA and operating margins, especially amid rising staff, energy, and medical supply costs.
- Pharmacy & Diagnostics Performance: Growth in Apollo Pharmacy and diagnostic services, which support steady cash flows.
- Digital Health & Telemedicine: Progress of Apollo 24/7 and other digital platforms in driving user engagement and revenues.
- Cost Management: Control over employee expenses, administrative costs, and procurement efficiency.
Final Thoughts
Apollo Hospitals Enterprise will announce its Q3 FY26 results on 10th February 2026. Analysts expect 11% revenue growth, a 12% rises in PAT, and a 4.44% fall in EBITDA. Apollo Hospitals Enterprise Revenue growth from hospitals and digital health platforms, margin trends amid rising costs, and occupancy levels reflecting patient demand.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Alfred Herbert India Ltd Q3 Results FY26 Preview: PAT falls 3%
Salora International Q3 Results FY26 Preview: PAT falls 18.54%
Kuantum Papers Q3 Results FY26 Preview: PAT falls 29.85%
AK Capital Services Ltd Q3 Results FY26 Preview: PAT falls 16.86%
Recent Articles

Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026

Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026

Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026

Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





